



## **PrIME receives GMP certification from the Health Sciences Authority of Singapore**

**7<sup>th</sup> July 2016**, PrIME Biologics is pleased to announce it has received Good Manufacturing Practice (**GMP**) certification from the Health Sciences Authority of Singapore (**HSA**) for the production of Albumin from plasma. This certificate is valid for three years.

GMP certification represents the culmination of the extensive work by our dedicated team of Scientists and Engineers over the last two years. The certificate validates the PrIME technology as a viable pharmaceutical process for the production of plasma products for human use.

This is the first new plasma production process approved by a regulator since the introduction of Chromatography in the early 1980s. Most notably, this is the first plasma product manufactured without any upstream processing of plasma including ethanol precipitation or cryoprecipitation.

This is also the first plasma fractionation facility to be setup in South East Asia.

The Board and Management of PrIME would like to thank all of our shareholders for their support over the past years and look forward to producing commercial batches of albumin in the near future. The company aims to manufacture other plasma based therapeutic proteins and will apply for subsequent regulatory approval for each of these.

### **About PrIME Biologics**

PrIME Biologics is a Singapore-based biotech company that has developed a disposable therapeutic plasma manufacturing process based on PrIME technology—**P**reparative **I**solation by **M**embrane **E**lectrophoresis. PrIME is pioneering this technique in its plasma manufacturing plant in Singapore to address the US\$1 billion Asian plasma derivative market.

The PrIME process almost doubles product yields to more than 90% while increasing product safety and removing viruses, bacteria, endotoxins and prions. In addition, the PrIME Biologics process reduces the time it takes to produce multiple plasma products from days to hours. The initial application for the PrIME process will be the Currently Unprocessable Plasma, which represents approximately 50% of all the plasma collected in many Asian countries.

### **PrIME Biologics Contact:**

Dr Hari Nair  
Executive Chairman  
Office: +65 6410 2410  
hari.nair@primebiologics.com